within Pharmacolibrary.Drugs.N_NervousSystem.N05A_Antipsychotics.N05AH05_Asenapine;

model Asenapine_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.02,
    Cl = 1.4444444444444446e-05,
    adminDuration = 600,
    adminMass = 5 / 1000000,
    adminCount = 1,
    Vd = 0.02,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.016666666666666666,
    Tlag = 600,
    Vdp = 0.376,
    k12 = 8.694444444444445e-05,
    k21 = 8.694444444444445e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Asenapine_1</td></tr><tr><td>ATC code:</td><td>N05AH05_1</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>20.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>52.0</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Asenapine is an atypical antipsychotic drug indicated for the treatment of schizophrenia and bipolar disorder. It acts as an antagonist at multiple serotonergic, dopaminergic, and adrenergic receptors. It is approved and currently used as a sublingual or transdermal medication.</p><h4>Pharmacokinetics</h4><p>Healthy adult subjects, oral (swallowed) administration, single dose for comparison</p><h4>References</h4><ol><li><p>Dogterom, P, et al., &amp; Troyer, MD (2018). Asenapine pharmacokinetics and tolerability in a pediatric population. <i>Drug design, development and therapy</i> 12 2677–2693. DOI:<a href=\"https://doi.org/10.2147/DDDT.S171475\">10.2147/DDDT.S171475</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30214156/\">https://pubmed.ncbi.nlm.nih.gov/30214156</a></p></li><li><p>Rado, J, &amp; Janicak, PG (2012). Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients. <i>Drugs &amp; aging</i> 29(10) 783–791. DOI:<a href=\"https://doi.org/10.1007/s40266-012-0009-0\">10.1007/s40266-012-0009-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23018584/\">https://pubmed.ncbi.nlm.nih.gov/23018584</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05AH05_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Asenapine_1;
